Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors
← catalyst calendarSponsored by Seagen, a wholly owned subsidiary of Pfizer (industry) · PFE — their whole pipeline →. With Merck Sharp & Dohme LLC.
Phase
Phase 2
Status
Completed
Study type
Interventional
Design
Na · None · Treatment
Enrollment
161actual
Sites
90
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-01-26 | actual | When the study began enrolling |
| Primary completion | 2026-02-03 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-02-03 | actual | The whole study's end, after follow-up |
| First posted | 2020-10-30 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-06 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Melanoma
- Non-small Cell Lung Cancer
- Squamous Cell Carcinoma of the Head and Neck
Interventions
- Drug: brentuximab vedotin — also filed as ADCETRIS
- Drug: pembrolizumab — also filed as KEYTRUDA®
Primary outcome
what the primary-completion date above is the date OFConfirmed objective response rate (ORR) based on investigator assessment using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) criteria
measured Up to approximately 2 years
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed